Triple negative breast cancer (TNBC) is defined by the lack of expression of hormone receptors or lack of overexpression of the human epidermal growth factor receptor 2 (HER2), and as such, TNBC traditionally derives limited benefit from targeted therapies. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.